Collaborative working between medical professionals and healthcare organisations has long been a positive driver for advancements in patient care and the development of innovative medicine. Medical professionals and the organisations with whom they work provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and disease management experience. Furthermore, as the primary point of contact with patients, the medical professional can offer invaluable expert knowledge on patient outcomes and therapy management. This helps to adapt our products to better suit patients and thereby improve patient care overall.
Healthcare professionals and organisations should be fairly compensated for the services they provide to pharmaceutical companies. The European Federation of Pharmaceutical Industries and Associations (EPFIA) Code of Practice provides accuracy and transparency in disclosing the scope and value of such collaborative work, and it is an important for building greater trust between the pharmaceutical industry, medical community and patients.
In the pharmaceutical industry, the Transfer of Value refers to any payment or benefit given to healthcare professionals (HCPs) or healthcare organizations (HCOs) to promote transparency and trust. These transfers can include monetary payments, grants, donations, sponsorships, consultancy fees, and funding for research and education.
Although our company is not an EFPIA member and thus not obliged to publish Transfer of Value (ToV) under the EFPIA Transparency code, we believe it is essential for these transfers to be disclosed to ensure compliance with the highest ethical standards and avoid conflicts of interest.
Producing transparency reporting is an opportunity to demonstrate our commitment to the values and principles behind the EFPIA Code of Practice and other transparency requirements in Europe.
We suggest that you read our methodology before reviewing the data.
